The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Statins and the COVID-19 main protease: in silico evidence on direct interaction
Open accessAbstract
INTRODUCTION: No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COVID-19 Mpro inhibitors, using a molecular docking study. MATERIAL AND METHODS: Molecular docking was performed using AutoDock/Vina, a computational docking program. SARS-CoV-2 Mpro was docked with all statins, while antiviral and antiretroviral drugs - favipiravir, nelfinavir, and lopinavir - were used as standards for comparison. RESULTS: The binding energies obtained from the docking of 6LU7 with native ligand favipiravir, nelfinavir, lopinavir, simvastatin, rosuvastatin, pravastatin, pitavastatin, lovastatin, fluvastatin, and atorvastatin were -6.8, -5.8, -7.9, -7.9, -7.0, -7.7, -6.6, -8.2, -7.4, -7.7, and -6.8 kcal/mol, respectively. The number of hydrogen bonds between statins and amino acid residues of Mpro were 7, 4, and 3 for rosuvastatin, pravastatin, and atorvastatin, respectively, while other statins had two hydrogen bonds. CONCLUSIONS: These results indicate, based upon the binding energy of pitavastatin, rosuvastatin, lovastatin, and fluvastatin, that statins could be efficient SARS-CoV-2 Mpro inhibitors. This is supported by the fact that the effects of some statins, especially pitavastatin, have a binding energy that is even greater than that of protease or polymerase inhibitors. However, further research is necessary to investigate their potential use as drugs for COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Dong, L., Hu, S., & Gao, J. (2020) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2020.01012 · Cited by 1,390
Going global – Travel and the 2019 novel coronavirus
Rodríguez-Morales, A. J., MacGregor, K., Kanagarajah, S., Patel, D., & Schlagenhauf, P. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101578 · Cited by 349
Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
Lee, P.-I., & Hsueh, P.-R. (2020) · Journal of Microbiology, Immunology and Infection · doi:10.1016/j.jmii.2020.02.001 · Cited by 327
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 301
Khaerunnisa, S., Kurniawan, H., Awaluddin, R., Suhartati, S., & Soetjipto, S. (2020) · doi:10.20944/preprints202003.0226.v1 · Cited by 256
Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, Banach, M., Serban, C., Sahebkar, A., Mikhailidis, D. P., Ursoniu, S., Ray, K. K., Rysz, J., Toth, P. P., Muntner, P., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0459-4 · Cited by 217
Self-citationChruściel, P., Sahebkar, A., Rembek-Wieliczko, M., Serban, M.-C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Mosteoru, S., Blaha, M. J., Martin, S. S., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.897 · Cited by 194
Self-citationParizadeh, S. M. R., Azarpazhooh, M. R., Moohebati, M., Nematy, M., Ghayour‐Mobarhan, M., Tavallaie, S., Rahsepar, A. A., Amini, M., Sahebkar, A., Mohammadi, M., et al. (2011) · Lipids · doi:10.1007/s11745-010-3517-x · Cited by 180
Self-citationSahebkar, A., Kotani, K., Serban, C., Ursoniu, S., Mikhailidis, D. P., Jones, S. R., Ray, K. K., Blaha, M. J., Rysz, J., Toth, P. P., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.022 · Cited by 178
Self-citation
Cited by
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
Self-citationZhang, X.-J., Qin, J.-J., Cheng, X., Shen, L., Zhao, Y.-C., Yuan, Y., Lei, F., Chen, M.-M., Yang, H., Bai, L., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.015 · Cited by 474
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Ž., et al. (2022) · Mediators of Inflammation · doi:10.1155/2022/8732360 · Cited by 136
Self-citation
Metadata
- Authors
- Reiner, Ž., Hatamipour, M., Banach, M., Pirro, M., Al-Rasadi, K., Jamialahmadi, T., Radenkovic, D., Montecucco, F., & Sahebkar, A.
- Venue
- Archives of Medical Science
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2020
- Volume
- 16
- Issue
- 3
- Pages
- 490-496
- ISSN
- 1734-1922 (ISSN-L)
- OpenAlex
- W3023838751
- Cited by
- 263
- References
- 25
- FWCI
- 28.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statins and the COVID-19 main protease: in silico evidence on direct interaction. https://app.cochat.ai/papers/10.5114/aoms.2020.94655
- The paper
- Reiner, Ž., Hatamipour, M., Banach, M., Pirro, M., Al-Rasadi, K., Jamialahmadi, T., Radenkovic, D., Montecucco, F., & Sahebkar, A. (2020). Statins and the COVID-19 main protease: in silico evidence on direct interaction. Archives of Medical Science. https://doi.org/10.5114/aoms.2020.94655
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.